Current Overview of Statin-Induced Myopathy

American Journal of Medicine

Volumn 116, Issue 6, 2004, Pages 408-416

  Rosenson, Robert S ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CHOLESTEROL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG TOLERABILITY; HUMAN; LIPOPHILICITY; METABOLIC DISORDER; MYALGIA; MYOPATHY; MYOSITIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ANTICHOLESTEREMIC AGENTS; COST-BENEFIT ANALYSIS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MUSCULAR DISEASES; PREVALENCE; RISK FACTORS;

EID: 1542314891     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.10.033     Document Type: Review

References (94)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
2. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1301-1307.
3. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 335:1996;1001-1009.
4. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 279:1998;1615-1622.
5. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo-controlled trial. Lancet. 360:2002;7-22.
7. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER) a randomised controlled trial. Lancet. 360:2002;1623-1630.
8. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA) a multicentre randomised controlled trial. Lancet. 361:2003;1149-1158.
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 288:2002;2998-3007.
10. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation. 101:2000;207-213.
11. Pasternak R.C., Smith S.C. Jr, Bairey-Merz C.N., et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation. 106:2002;1024-1028.
12. Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 346:2002;539-540.
13. Scott H.D., Rosenbaum S.E., Waters W.J., et al. Rhode Island physicians' recognition and reporting of adverse drug reactions. R I Med J. 70:1987;311-316.
14. Evans M., Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle are all statins the same? Drug Saf. 25:2002;649-663.
15. Ucar M., Mjorndal T., Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 22:2000;441-457.
16. Omar M.A., Wilson J.P. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 36:2002;288-295.
17. Grundy S.M. Can statins cause low-grade myopathy? Ann Intern Med. 137:2002;617-618.
18. Levy Y., Leibowitz R., Aviram M., et al. Reduction of plasma cholesterol by lovastatin normalizes erythrocyte membrane fluidity in patients with severe hypercholesterolaemia. Br J Clin Pharmacol. 34:1992;427-430.
19. Morita I., Sato I., Ma L., Murota S. Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin. Endothelium. 5:1997;107-113.
20. Lijnen P., Celis H., Fagard R., et al. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J Hypertens. 12:1994;59-64.
21. Sonoda Y., Gotow T., Kuriyama M., et al. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve. 17:1994;891-897.
22. Mastaglia F.L. Adverse effects of drugs on muscle. Drugs. 24:1982;304-321.
23. Philips P.S., Haas R.H., Bannykh S., et al. Statin-associated myopathy and normal creatine kinase levels. Ann Intern Med. 137:2002;581-585.
24. Bliznakov E.G. Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case - a modern Pandora's box. Biomed Pharmacother. 56:2002;56-59.
25. Chu P.H., Chen W.J., Chiang C.W., Lee Y.S. Rhabdomyolysis, acute renal failure and hepatopathy induced by lovastatin monotherapy. Jpn Heart J. 38:1997;541-545.
26. Bliznakov E.G., Wilkins D.J. Biochemical and clinical consequences of inhibiting coenzyme Q biosynthesis by lipid-lowering HMG-Co A reductase inhibitors (statins) a critical overview. Adv Ther. 15:1998;218-228.
27. Watts G.F., Castelluccio C., Rice-Evans C., et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol. 46:1993;1055-1057.
28. Bargossi A.M., Battino M., Gaddi A., et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int J Clin Lab Res. 24:1994;171-176.
29. Laaksonen R., Jokelainen K., Laakso J., et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol. 77:1996;851-854.
30. Bleske B.E., Willis R.A., Anthony M., et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J. 142:2001;E2.
31. Gaist D., Rodríguez L.A.G., Huerta C., et al. Lipid-lowering drugs and risk of myopathy a population-based follow-up study. Epidemiology. 12:2001;565-569.
32. Farmer J.A. Learning from the cerivastatin experience. Lancet. 358:2001;1383-1385.
33. Furberg C.D., Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2:2001;205-207.
34. Roca B., Calvo B., Monferrer R. Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy. Ann Pharmacother. 36:2002;730-731.
35. Backman J.T., Kyrklund C., Neuvonen M., Neuvonen P.J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther. 72:2002;685-691.
36. Rosenson R.S. Statins and the risk of rhabdomyolysis. J Endocrinol Invest. 25:2002;577.
37. Le Quintrec J.S., Le Quintrec J.L. Drug-induced myopathies. Baillieres Clin Rheumatol. 5:1991;21-38.
38. McLean R.M., Podell D.N. Bone and joint manifestations of hypothyroidism. Semin Arthritis Rheum. 24:1995;282-290.
39. Madariaga M.G. Polymyositis-like syndrome in hypothyroidism review of cases reported over the past twenty-five years. Thyroid. 12:2002;331-336.
40. Hamilton-Craig I. Statin-associated myopathy. Med J Aust. 175:2001;486-489.
41. Crouch M.A. Effective use of statins to prevent coronary heart disease. Am Fam Physician. 63:2001;309-320.
42. Olsson A.G., McTaggart F., Raza A. Rosuvastatin a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 20:2002;303-328.
43. McTaggart F., Buckett L., Davidson R., et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 87:2001;28B-32B.
44. Corsini A., Bellosta S., Baetta R., et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins [published correction in Pharmacol Ther 2000;86:199]. Pharmacol Ther. 84:1999;413-428.
45. Hamelin B.A., Turgeon J. Hydrophilicity/lipophilicity relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 19:1998;36-37.
46. Masters B.A., Palmoski M.J., Flint O.P., et al. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol. 131:1995;163-174.
47. Gadbut A.P., Caruso A.P., Galper J.B. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol. 27:1995;2397-2402.
48. Nakahara K., Kuriyama M., Sonoda Y., et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol. 152:1998;99-106.
49. Reijneveld J.C., Koot R.W., Bredman J.J., et al. Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr Res. 39:1996;1028-1035.
50. Christians U., Jacobsen W., Floren L.C. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients are statins mechanically similar? Pharmacol Ther. 80:1998;1-34.
51. Sica D.A., Gehr T.W. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis considerations in the renal failure patient. Curr Opin Nephrol Hypertens. 11:2002;123-133.
52. Sica D.A., Gehr T.W. Rhabdomyolysis and statin therapy relevance to the elderly. Am J Geriatr Cardiol. 11:2002;48-55.
53. Cardiovascular Prescribing Guide. 5th ed. Montvale, New Jersey: Medical Economics Company Inc.; 2001:435.
54. Tolbert J.A. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol. 62:1988;28J-34J.
55. Schachter M. Statins, drug interactions and cytochrome P450. Br J Cardiol. 8:2001;311-317.
56. Neuvonen P.J., Jalava K.M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 60:1996;54-61.
57. Neuvonen P.J., Kantola T., Kivisto K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 63:1998;332-341.
58. Kantola T., Kivisto K.T., Neuvonen P.J. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 64:1998;58-65.
59. Prueksaritanont T., Subramanian R., Fang X., et al. Glucuronidation of statins in animals and humans a novel mechanism of statin lactonization. Drug Metab Dispos. 30:2002;505-512.
60. Prueksaritanont T., Wright S.D., Tang C., et al. Metabolic interactions between gemfibrozil and statins in human liver preparations. Circulation. 106:(suppl):2002;II-185.
61. Prueksaritanont T., Tang C., Qiu Y., et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 30:2002;1280-1287.
62. Pan W.J., Gustavson L.E., Achari R., et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacother. 40:2000;316-323.
63. Martin P.D., Dane A.L., Schneck D.W., Warwick M.J. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibrate acid in healthy male volunteers. Clin Ther. 25:2003;459-471.
64. Rosenson R.S. The rationale for combination therapy. Am J Cardiol. 90:2002;2K-7K.
65. Shek A., Ferrill M.J. Statin-fibrate combination therapy. Ann Pharmacother. 35:2001;908-917.
66. Duell P.B., Connor W.E., Illingworth D.R. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol. 81:1998;368-369.
67. van Puijenbroeck E.P., Du Buf-Vereijken P.W., Spooren P.F., van Doormaal J.J. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med. 240:1996;403-404.
68. Bermingham R.P., Whitsitt T.B., Smart M.L., et al. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. Am J Health Syst Pharm. 57:2000;461-464.
69. Miller D.B., Spence J.D. Clinical pharmacokinetics of fibric acid and derivatives (fibrates). Clin Pharmacokinet. 34:1998;155-162.
70. Wen X., Wang J.S., Backman J.T., et al. Gemfibrozil is a potent inhibitor of human cytochrome p450 2C9. Drug Metab Dispos. 29:2001;1359-1361.
71. Kyrklund C., Backman J.T., Kivistö K.T., et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 69:2001;340-345.
72. Omar M.A., Wilson J.P., Cox T.S. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother. 35:2001;1096-1107.
73. Ellen R.L.B., McPherson R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am J Cardiol. 81:1998;60B-65B.
74. Reaven P., Witztum J.L. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med. 109:1998;597-598.
75. Davignon J., Roederer G., Montigny M., et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol. 73:1994;339-345.
76. Hiatt J.G., Shamsie S.G., Schectman G. Discontinuation rates of cholesterol-lowering medications implications for primary care. Am J Manag Care. 5:1999;437-444.
77. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med. 341:1999;498-511.
78. Kennedy H.L., Rosenson R.S. Physicians' interpretation of "class effects:" a need for thoughtful re-evaluation. J Am Coll Cardiol. 40:2002;19-26.
79. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
80. Pederson T.R., Olsson A.G., Faergeman O., et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 97:1998;1453-1460.
81. Sacks F.M., Moye L.A., Davis B.R., et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 97:1998;1446-1452.
82. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 97:1998;1440-1445.
83. Simes R.J., Marschner I.C., Hunt D., et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation. 105:2002;1162-1169.
84. Jones P.H., Davidson M.H., Stein E.A., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 92:2003;152-160.
85. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins implications for cardiovascular event reduction. JAMA. 279:1998;1643-1650.
86. Hunninghake D., Bakker-Arkema R.G., Wigand J.P., et al. Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract. 47:1998;349-356.
87. Brown A.S., Bakker-Arkema R.G., Yellen L., et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol. 32:1998;665-672.
88. Andrews T.C., Ballantyne C.M., Hsia J.A., Kramer J.H. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med. 111:2001;185-191.
89. Pfeffer M.A., Keech A., Sacks F.M., et al. Safety and tolerability of pravastatin in long-term clinical trials Prospective Pravastatin Pooling (PPP) Project. Circulation. 105:2002;2341-2346.
90. Wiklund O., Angelin B., Bergman M., et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 94:1993;13-20.
91. Athyros V.G., Papageorgiou A.A., Hatzikonstandinou H.A., et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 80:1997;608-613.
92. Iliadis E.A., Rosenson R.S. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol. 22:1999;25-28.
93. Davidson M.H. Does differing metabolism by cytochrome p450 have clinical importance? Curr Atheroscler Rep. 2:2000;14-19.
94. Smith C.C., Bernstein L.I., Davis R.B., et al. Screening for statin-related toxicity the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med. 163:2003;688-692.